spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Trastuzumab 

 HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 5 Jul 2024
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 May 2024
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili(TM). Enters U.S. Ophthalmology Market
Biopharmaceuticals Generics Ophthalmology FDA
 HSMN NewsFeed - 10 Apr 2024
TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 16 Jun 2020
EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2019
World-Renowned Cancer Leader Brian Leyland-Jones Named Chairman of NED Biosystems' Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 May 2019
FogPharma Strengthens New Modality Drug Hunting Team with Appointment of Howard Stern as Chief Scientific Officer and Peter Fekkes as Vice President of Discovery Bioscience
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Oct 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
Biopharmaceuticals Generics Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 21 Jun 2018
Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study
Diagnostics Oncology
 HSMN NewsFeed - 23 Mar 2018
Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin(R)) For The Treatment Of Three Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Mar 2018
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 1 Dec 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Jul 2017
Amgen and Allergan Submit Biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 10 Jul 2017
FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 May 2017
Formation Biologics Announces Dosing of First Patient in a Phase I/IIa Trial of AVID100, Closing of Series B Financing, and Appointment of Dr. Anthony Tolcher to its Board of Directors
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 24 Apr 2017
Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2017
Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2017
Mylan Announces Global Settlement and License Agreements with Genentech and Roche on Herceptin(R)
Biopharmaceuticals Oncology Generics Licensing
 HSMN NewsFeed - 6 Oct 2016
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Aug 2016
Lilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jul 2016
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Biopharmaceuticals
 HSMN NewsFeed - 24 Feb 2016
Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs
Biopharmaceuticals Oncology Venture Capital Licensing
 HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Aug 2014
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Feb 2014
Mylan Launches First Trastuzumab Biosimilar, Hertraz(TM), in India
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 20 Nov 2013
ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla(R) in the European Union
Biopharmaceuticals Drug Delivery Oncology Regulatory
 HSMN NewsFeed - 2 Jul 2013
FDA Grants Genentech’s Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Nov 2012
ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Oct 2012
Abbott's ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 1 Oct 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2012
New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech’s Perjeta
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Mar 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Mar 2012
Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 30 Jan 2012
ImmunoGen, Inc. Announces Addition of Kristine Peterson and Dean Mitchell to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jan 2012
Galena Biopharma Initiates Patient Enrollment in NeuVax(TM) Phase 3 PRESENT Trial to Prevent Breast Cancer Recurrence
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2011
Galena Biopharma Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2011
Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy Selection
Diagnostics Personalized Medicine Oncology FDA
 HSMN NewsFeed - 22 Aug 2011
FDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis
Diagnostics Oncology FDA
 HSMN NewsFeed - 15 Jul 2011
Pertuzumab Combined With Herceptin and Chemotherapy Significantly Extended the Time People With HER2-Positive Metastatic Breast Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2011
RXi Pharmaceuticals Aggressively Moves into Late-Stage Clinical Development with the Agreement to Acquire Apthera, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 16 Feb 2011
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera(R) (rituximab)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jan 2011
ImmunoGen, Inc. Appoints Theresa Wingrove, Ph.D., as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Dec 2010
Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women With Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2010
Genentech Provides Update on FDA Application for T-DM1
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jul 2010
Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Apr 2010
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2010
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2010
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
Biopharmaceuticals Personalized Medicine Oncology
 HSMN NewsFeed - 8 Jan 2010
Dr. Mark W. Schwartz Joins Apthera as President & CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jan 2010
Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Dec 2009
ImmunoGen, Inc. Appoints Suzanne Cadden as Vice President, Regulatory Affairs & Quality
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Oct 2009
Seattle Genetics Names Head of Commercial and Announces Management Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Aug 2009
Aperio Receives Second FDA Clearance for HER2 Image Analysis Application for Breast Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 4 Jun 2009
Apthera Announces Product License Agreement With Kwang Dong Pharmaceutical Co., Ltd.
Biopharmaceuticals Oncology Licenisng
 HSMN NewsFeed - 29 May 2009
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2009
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Oct 2008
Ikonisys Receives FDA Clearance for Non-Invasive, HER-2 Breast Cancer Test
Diagnostics Oncology FDA
 HSMN NewsFeed - 15 Sep 2008
Invitrogen, Biocare to Market FDA Approved Breast Cancer Test
Diagnostics FDA
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2008
ABRAXANE(R) in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2008
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2008
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Mar 2008
Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jan 2008
Kosan Appoints Helen S. Kim as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Dec 2007
GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Dec 2007
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2007
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2007
ImmunoGen, Inc. Hires John Tagliamonte as Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Oct 2007
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Oct 2007
Ventana Submits INFORM(TM) HER2 SISH DNA Probe Assay for FDA Approval
Diagnostics Oncology FDA
 HSMN NewsFeed - 3 Oct 2007
ImmunoGen, Inc. Hires Craig Barrows as Vice President, General Counsel and Secretary
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2007
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Aug 2007
Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jul 2007
ImmunoGen, Inc. Announces Departure of Pauline Jen Ryan
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
ImmunoGen, Inc. Announces Clinical Data Reported at ASCO
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Glaxosmithkline Reports Positive New Data on Tykerb(R)(Lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2007
FDA Approves TYKERB(R) (lapatinib) in Combination With Xeloda(R) (capecitabine) for the Treatment of Advanced or Metastatic Breast Cancer in Women Who Have Progressed on Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Mar 2007
VMSI Launches Automated HER2 Silver for Breast Cancer Pathology
Diagnostics Oncology
 HSMN NewsFeed - 6 Mar 2007
ImmunoGen, Inc. Announces Departure of Walter Blattler
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Feb 2007
GSK Initiates First Global Phase III Study of TYKERB(R) (lapatinib) in Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2007
FDA Clears BioView Duet(TM) System for Automated FISH Scanning of Breast Cancer Tissue Specimens
Diagnostics Oncology FDA
 HSMN NewsFeed - 18 Jan 2007
Ventana Receives FDA Approval for Rabbit Monoclonal Antibody
Diagnostics Oncology FDA
 HSMN NewsFeed - 17 Jan 2007
Genentech Announces Senior Vice President and Vice President Promotions in Commercial, Legal and Product Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2007
NCCN Offers HER2 Testing for Breast Cancer Patients(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2007
NCCN Updates Antiemesis Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2007
Kosan Appoints Jane Green as Vice President, Corporate Communications
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Dec 2006
Landmark Tykerb(R) (Lapatinib) Data Published in the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Dec 2006
ImmunoGen, Inc. Announces that sanofi-aventis Has Entered into an Option Agreement for Expanded Access to the Company's TAP Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 20 Dec 2006
Kosan Announces License of Motilin Agonist Program to Pfizer
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Dec 2006
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2006
Data Presented Today Show ARIMIDEX(R) Combined With Herceptin(R) Extended Progression-Free Survival in Patients With Advanced HER-2-Positive and Hormone Receptor-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2006
Lapatinib (Tykerb(R)) to be Evaluated in Early Stage Disease in Adjuvant Breast Cancer Settings Internationally
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Oct 2006
Diatos Strengthens Management Team with the Appointment of New Chief Medical Officer and New Chief Sales & Marketing Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Oct 2006
Patients With HER2-Positive Breast Cancer Significantly Benefit From Addition of Xeloda to Herceptin and Taxotere Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jul 2006
ImmunoGen, Inc. Grants Biotest AG Rights to Use ImmunoGen TAP Technology to Develop Novel Anticancer Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2006
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 May 2006
GlaxoSmithKline Demonstrates Progress of Oncology Portfolio; New Data to Be Presented at ASCO 2006
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 May 2006
Genentech Announces Vice President Appointments in Commercial Operations and Product Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 May 2006
ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 86

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 86 additional stories matching:
Trastuzumab
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.